Related Experiment Videos
[Antibioprophylaxis of Meningococcus group B meningitis. Must we implicate the use of the spiramycin]
Pathologie-Biologie
|May 1, 1987
Abstract:
A fatal meningitis due to a spiramycin-sensitive group B Neisseria meningitidis occurred 13 days after interruption of a prophylactic antimicrobial therapy with spiramycin. The efficacy of recommended antimicrobial preventive treatment is discussed with regard to this case, other published cases and to the known partial and short term eradication of the naso-pharyngeal carriage of Neisseria meningitidis.
Insights
A fatal meningitis case highlights the risks of interrupting prophylactic antimicrobial therapy. Spiramycin
Area of Science:
- Infectious Diseases
- Microbiology
- Epidemiology
Background:
- Group B Neisseria meningitidis can cause severe meningitis.
- Antimicrobial prophylaxis is used to prevent meningococcal disease spread.
- Spiramycin is an antibiotic used for prophylaxis.
Observation:
- A fatal meningitis case occurred 13 days after stopping spiramycin prophylaxis.
- The causative agent was a spiramycin-sensitive Neisseria meningitidis group B.
- This case suggests potential limitations of antimicrobial prophylaxis.
Findings:
- Spiramycin prophylaxis may not achieve long-term eradication of nasopharyngeal carriage.
- Interruption of prophylaxis can lead to disease recurrence or new infections.
- The efficacy of current meningococcal prophylaxis strategies needs re-evaluation.
Implications:
- Clinical guidelines for meningococcal prophylaxis may require revision.
- Further research is needed to optimize strategies for preventing meningococcal meningitis.
- Understanding carriage dynamics is crucial for effective disease control.